Terms: = Pancreatic cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
64 results:
1. Alteration of chromosome structure impacts gene expressions implicated in pancreatic ductal adenocarcinoma cells.
Han W; Shi D; Yang Q; Li X; Zhang J; Peng C; Yan F
BMC Genomics; 2024 Feb; 25(1):206. PubMed ID: 38395755
[TBL] [Abstract] [Full Text] [Related]
2. Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma.
McIntyre SM; Preston WA; Walch H; Sharib J; Kundra R; Sigel C; Lidsky ME; Allen PJ; Morse MA; Chen W; Cercek A; Harding JJ; Abou-Alfa GK; O'Reilly EM; Park W; Balachandran VP; Drebin J; Soares KC; Wei A; Kingham TP; D'Angelica MI; Iacobuzio-Donahue C; Jarnagin WR
JCO Precis Oncol; 2024 Feb; 8():e2300534. PubMed ID: 38394469
[TBL] [Abstract] [Full Text] [Related]
3. Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.
Tsilimigras DI; Han X; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Chaucy F; Koerkamp BG; Endo I; Sasaki K; Aucejo F; Zhang XF; Zhu H; Pawlik TM
Ann Surg Oncol; 2024 May; 31(5):3087-3097. PubMed ID: 38347332
[TBL] [Abstract] [Full Text] [Related]
4. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
5. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
[TBL] [Abstract] [Full Text] [Related]
6. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
7. Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma.
Wang J; Shi Y; Chen J; Liu J; Zhao X; Pang J; Sun X; Tian Y; Ou Q; Xia F; Chen Y
Cancer Biol Ther; 2023 Dec; 24(1):2223375. PubMed ID: 37337460
[TBL] [Abstract] [Full Text] [Related]
8. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract] [Full Text] [Related]
9. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Rev Esp Patol; 2023; 56(1):32-44. PubMed ID: 36599598
[TBL] [Abstract] [Full Text] [Related]
10. [cancer Therapy Targeting Fusion Gene(fgfr2 Fusion Gene)in Biliary Tract cancer].
Hamaguchi T; Ueno M
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1040-1042. PubMed ID: 36281591
[TBL] [Abstract] [Full Text] [Related]
11. Exceptional Response to Erdafitinib in fgfr2-Mutated Metastatic pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract] [Full Text] [Related]
12. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying fgfr2 fusions or rearrangements: A phase II study.
Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
[TBL] [Abstract] [Full Text] [Related]
13. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de-Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Clin Transl Oncol; 2022 Nov; 24(11):2107-2119. PubMed ID: 36008616
[TBL] [Abstract] [Full Text] [Related]
14. Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Kuboki Y; Matsubara N; Bando H; Yoh K; Naito Y; Hirai H; Kurokawa Y; Kato T; Morizane C
Cancer Sci; 2023 Feb; 114(2):574-585. PubMed ID: 35838190
[TBL] [Abstract] [Full Text] [Related]
15. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary cancers Treated With Platinum-Based Chemotherapy.
Uson Junior PLS; Majeed U; Yin J; Botrus G; Sonbol MB; Ahn DH; Starr JS; Jones JC; Babiker H; Inabinett SR; Wylie N; Boyle AWR; Bekaii-Saab TS; Gores GJ; Smoot R; Barrett M; Nagalo B; Meurice N; Elliott N; Petit J; Zhou Y; Arora M; Dumbauld C; Barro O; Baker A; Bogenberger J; Buetow K; Mansfield A; Mody K; Borad MJ
JCO Precis Oncol; 2022 Jun; 6(1):e2100274. PubMed ID: 35666960
[TBL] [Abstract] [Full Text] [Related]
16. Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors.
Paolino G; Esposito I; Hong SM; Basturk O; Mattiolo P; Kaneko T; Veronese N; Scarpa A; Adsay V; Luchini C
Histopathology; 2022 Sep; 81(3):297-309. PubMed ID: 35583805
[TBL] [Abstract] [Full Text] [Related]
17. The Molecular Landscape of Pancreatobiliary cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
Umemoto K; Yamamoto H; Oikawa R; Takeda H; Doi A; Horie Y; Arai H; Ogura T; Mizukami T; Izawa N; Moore JA; Sokol ES; Sunakawa Y
J Natl Cancer Inst; 2022 Sep; 114(9):1279-1286. PubMed ID: 35583261
[TBL] [Abstract] [Full Text] [Related]
18. Molecular Characterization of KRAS Wild-type Tumors in Patients with pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract] [Full Text] [Related]
19. Deciphering Genetic Alterations of Taiwanese Patients with pancreatic Adenocarcinoma through Targeted Sequencing.
Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506
[TBL] [Abstract] [Full Text] [Related]
20. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
[TBL] [Abstract] [Full Text] [Related]
[Next]